» Articles » PMID: 18769939

Kidney Biopsy Findings in Heterozygous Fabry Disease Females with Early Nephropathy

Overview
Journal Virchows Arch
Date 2008 Sep 5
PMID 18769939
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Fabry disease is an X-linked glycosphingolipidosis caused by deficiency of alpha-galactosidase. Progressive chronic kidney disease (CKD) is a major cause of morbidity and mortality in males. Although 40% of heterozygous females may develop renal involvement, pathologic data on Fabry nephropathy in heterozygotes are scarce. We reviewed the kidney biopsies of four affected females who had normal to slightly sub-normal renal function, two of them with overt proteinuria. Chronic non-specific degenerative lesions and glycosphingolipid accumulation per cell type were semi-quantitatively assessed by light and electron microscopy. Cellular distribution of glycosphingolipid deposits was best assessed on semithin sections. Podocyte effacement was seen only in proteinuric patients. Combined analysis of our data with those of two earlier series showed that glomerular sclerosis and tubulointerstitial fibrosis are predictors of proteinuria and CKD stage. There was no histopathological evidence supporting a major role of vascular damage in the early pathogenesis of Fabry nephropathy in females.

Citing Articles

Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease.

Tuttolomondo A, Baglio I, Riolo R, Todaro F, Parrinello G, Miceli S Int J Mol Sci. 2024; 25(1).

PMID: 38203231 PMC: 10779326. DOI: 10.3390/ijms25010061.


The Impact of Kidney Biopsy for Fabry Nephropathy Evaluation on Patients' Management and Long-Term Outcomes: Experience of a Single Center.

Rusu E, Zilisteanu D, Ciobotaru L, Gherghiceanu M, Procop A, Jurcut R Biomedicines. 2022; 10(7).

PMID: 35884826 PMC: 9313342. DOI: 10.3390/biomedicines10071520.


A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease.

Najafian B, Silvestroni A, Sokolovskiy A, Tondel C, Svarstad E, Obrisca B Kidney Int. 2022; 102(1):173-182.

PMID: 35483528 PMC: 9233139. DOI: 10.1016/j.kint.2022.03.023.


Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review.

Caputo F, Lungaro L, Galdi A, Zoli E, Giancola F, Caio G Int J Environ Res Public Health. 2021; 18(6).

PMID: 33807115 PMC: 8005161. DOI: 10.3390/ijerph18063320.


Biomarkers of Fabry Nephropathy: Review and Future Perspective.

Levstek T, Vujkovac B, Trebusak Podkrajsek K Genes (Basel). 2020; 11(9).

PMID: 32962051 PMC: 7564978. DOI: 10.3390/genes11091091.


References
1.
Tosoni A, Nebuloni M, Zerbi P, Vago L, Comotti C, Sessa A . Ultrastructural study of renal involvement in two females with Anderson-Fabry disease. Ultrastruct Pathol. 2005; 29(3-4):203-7. DOI: 10.1080/01913120590951202. View

2.
Faraggiana T, Churg J, Grishman E, Strauss L, Prado A, Bishop D . Light- and electron-microscopic histochemistry of Fabry's disease. Am J Pathol. 1981; 103(2):247-62. PMC: 1903824. View

3.
Mundel P, Shankland S . Podocyte biology and response to injury. J Am Soc Nephrol. 2002; 13(12):3005-15. DOI: 10.1097/01.asn.0000039661.06947.fd. View

4.
Macdermot K, Holmes A, Miners A . Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001; 38(11):769-75. PMC: 1734754. DOI: 10.1136/jmg.38.11.769. View

5.
Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo Jr J . Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6):1206-52. DOI: 10.1161/01.HYP.0000107251.49515.c2. View